Company
SymbioTec GmbH was founded by Drs Volker Rusch and Michael Zeppezauer and started its operative business in 1999 in the Starterzentrum (start-up centre) of the University of the Saarland. In 2001 the company moved to the Science Park Saar 1 at the campus of the Saarland University.
SymbioTec GmbH has the goal of developing and marketing innovative products for therapy and diagnostics of life-threatening disease, such as cancer. Our range of products comprises optimised derivatives of naturally occurring proteins and peptides, especially histone derivatives. Histones are a normal part of the innate defence systems of all higher life forms. This group of agents is capable to attack tumour cells of various origins as well as microbes with multiple antibiotic resistance. By using the body’s own protein-derivatives for the development of a completely new class of drugs, we expect to revolutionize the treatment of cancer and infectious diseases. more…